



A Study of avutometinib (VS-6766) and defactinib in People with Mesonephric Gynecologic Cancer

Study Overview:

This study will test if avutometinib (VS-6766) in combination with defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer. Avutometinib and defactinib are both a type of drug called kinase inhibitors. Kinase inhibitors block cancer cell growth.

This is an open-label trial. Every patient will be treated with active study drugs, and their investigator will not be comparing it to a placebo. Avutometinib and defactinib are investigational drugs that have not been approved by the U.S. Food and Drug Administration (FDA).

Study (Protocol) Title: Single Arm Phase II Study of VS-6766 and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer

Study (Protocol) Numbers:

MSKCC ID: MED 22-165; IRB 22-392

Verastem ID: IST-VS-6766-006

Clinical Trial: NCT05787561

Study Drugs or Compounds: avutometinib (VS-6766) and defactinib (VS-6063)

Study Phase: Phase 2

Total Enrollment: 20 patients

Sponsor: Memorial Sloan Kettering Cancer Center (MSKCC)

Collaborators: Verastem Oncology

Principle Investigator: Rachel Grisham